Showing results (231-240 of 3,976) with videos related to

Sort By:
Pageof 398
European Journal of Heart Failure|March 3, 2022
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trialGerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, et al.
European Journal of Heart Failure|June 13, 2018
Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCATJustin L Grodin, Jeffrey M Testani, Ambarish Pandey, et al.
European Journal of Heart Failure|May 29, 2018
Advanced heart failure: a position statement of the Heart Failure Association of the European Society of CardiologyMaria G Crespo-Leiro, Marco Metra, Lars H Lund, et al.
European Journal of Heart Failure|May 29, 2018
Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey IICecilia M Linde, Camilla Normand, Nigussie Bogale, et al.
European Journal of Heart Failure|May 5, 2018
Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival TrialSøren L Kristensen, Rasmus Rørth, Pardeep S Jhund, et al.
European Journal of Heart Failure|February 24, 2006
Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamicsMartín J García-González, Alberto Domínguez-Rodríguez, Julio J Ferrer-Hita, et al.
European Journal of Heart Failure|January 3, 2006
Non-cardiac determinants of NT-proBNP levels in the elderly: relevance of haematocrit and hepatic steatosisAntonio Muscari, Annalisa Berzigotti, Giampaolo Bianchi, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|September 2, 2008
Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failureAlexander Göhler, Annette Conrads-Frank, Stewart S Worrell, et al.
European Journal of Heart Failure|April 15, 2010
Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failureSilvia Meili-Butz, Katrin Bühler, Dietlinde John, et al.
Pageof 398